Jennifer S Ford1, Emily S Tonorezos2, Ann C Mertens3, Melissa M Hudson4, Jacqueline Casillas5, Barbara M Foster6, Chaya S Moskowitz2, Stephanie M Smith7, Joanne F Chou2, George Buchanan8, Leslie L Robison4, Kevin C Oeffinger9. 1. Hunter College and Graduate Center, City University of New York, New York, New York. 2. Memorial Sloan Kettering Cancer Center, New York, New York. 3. Emory University School of Medicine, Atlanta, Georgia. 4. St Jude Children's Research Hospital, Memphis, Tennessee. 5. University of California Los Angeles School of Medicine, Los Angeles, California. 6. American Board of Obstetrics and Gynecology, Dallas, Texas. 7. Stanford University School of Medicine, Palo Alto, California. 8. University of Texas Southwestern Medical Center, Dallas, Texas. 9. Duke University, Durham, North Carolina.
Abstract
BACKGROUND: Optimal risk-based survivor health care includes surveillance for late effects and education targeted at reducing or preventing risky health behaviors. Understanding the reasons for a lack of risk-based follow-up care is essential. METHODS: Adult participants from the Childhood Cancer Survivor Study were surveyed about having a cancer-related visit in the past 2 years and the likelihood of having a cancer-related visit in the future. Additional factors thought to be related to the primary outcomes were also assessed. RESULTS: Nine hundred seventy-five survivors completed the survey. Twenty-seven percent (95% confidence interval [CI], 24%-30%) had a cancer-related medical visit in the previous 2 years, and 41% (95% CI, 38%-44%) planned to have such a visit within the next 2 years. The likelihood of having had a cancer-related visit within the last 2 years was higher among survivors assigning greater importance to these visits (relative risk [RR], 1.2; 95% CI, 1.1-1.3), perceiving greater susceptibility to health problems (RR, 1.2; 95% CI, 1.1-1.3), having a moderate to life-threatening chronic health problem related to their cancer (RR, 2.1; 95% CI, 1.7-2.7), seeing a primary care provider for a cancer-related problem (RR, 1.3; 95% CI, 1.0-1.6), having a cancer treatment summary (RR, 1.3; 95% CI, 1.0-1.6), and endorsing greater confidence in physicians' abilities to address questions and concerns (RR, 1.2; 95% CI, 1.0-1.3). CONCLUSIONS: Educational interventions improving awareness of treatment history and susceptibility to cancer-related late effects and corresponding risk-based care are likely to be beneficial for survivors of childhood cancers.
BACKGROUND: Optimal risk-based survivor health care includes surveillance for late effects and education targeted at reducing or preventing risky health behaviors. Understanding the reasons for a lack of risk-based follow-up care is essential. METHODS: Adult participants from the Childhood Cancer Survivor Study were surveyed about having a cancer-related visit in the past 2 years and the likelihood of having a cancer-related visit in the future. Additional factors thought to be related to the primary outcomes were also assessed. RESULTS: Nine hundred seventy-five survivors completed the survey. Twenty-seven percent (95% confidence interval [CI], 24%-30%) had a cancer-related medical visit in the previous 2 years, and 41% (95% CI, 38%-44%) planned to have such a visit within the next 2 years. The likelihood of having had a cancer-related visit within the last 2 years was higher among survivors assigning greater importance to these visits (relative risk [RR], 1.2; 95% CI, 1.1-1.3), perceiving greater susceptibility to health problems (RR, 1.2; 95% CI, 1.1-1.3), having a moderate to life-threatening chronic health problem related to their cancer (RR, 2.1; 95% CI, 1.7-2.7), seeing a primary care provider for a cancer-related problem (RR, 1.3; 95% CI, 1.0-1.6), having a cancer treatment summary (RR, 1.3; 95% CI, 1.0-1.6), and endorsing greater confidence in physicians' abilities to address questions and concerns (RR, 1.2; 95% CI, 1.0-1.3). CONCLUSIONS: Educational interventions improving awareness of treatment history and susceptibility to cancer-related late effects and corresponding risk-based care are likely to be beneficial for survivors of childhood cancers.
Authors: Elyse R Park; Anne C Kirchhoff; Giselle K Perez; Wendy Leisenring; Joel S Weissman; Karen Donelan; Ann C Mertens; James D Reschovsky; Gregory T Armstrong; Leslie L Robison; Mariel Franklin; Kelly A Hyland; Lisa R Diller; Christopher J Recklitis; Karen A Kuhlthau Journal: J Clin Oncol Date: 2015-02-02 Impact factor: 44.544
Authors: Tara O Henderson; Alison Amsterdam; Smita Bhatia; Melissa M Hudson; Anna T Meadows; Joseph P Neglia; Lisa R Diller; Louis S Constine; Robert A Smith; Martin C Mahoney; Elizabeth A Morris; Leslie L Montgomery; Wendy Landier; Stephanie M Smith; Leslie L Robison; Kevin C Oeffinger Journal: Ann Intern Med Date: 2010-04-06 Impact factor: 25.391
Authors: Siobhan M Phillips; Lynne S Padgett; Wendy M Leisenring; Kayla K Stratton; Ken Bishop; Kevin R Krull; Catherine M Alfano; Todd M Gibson; Janet S de Moor; Danielle Blanch Hartigan; Gregory T Armstrong; Leslie L Robison; Julia H Rowland; Kevin C Oeffinger; Angela B Mariotto Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-04 Impact factor: 4.254
Authors: James L Klosky; Darlene K Cash; Joanna Buscemi; Shelly Lensing; Danette M Garces-Webb; Wenyan Zhao; Sally Wiard; Melissa M Hudson Journal: J Cancer Surviv Date: 2008-09-12 Impact factor: 4.442
Authors: Paul Craig Nathan; Christopher Keller Daugherty; Kristen Elizabeth Wroblewski; Mackenzie Louise Kigin; Tom Vernon Stewart; Fay Jarmila Hlubocky; Eva Grunfeld; Marie Elisabeth Del Giudice; Leigh-Anne Evelyn Ward; James Mahlon Galliher; Kevin Charles Oeffinger; Tara Olive Henderson Journal: J Cancer Surviv Date: 2013-03-08 Impact factor: 4.442
Authors: Paul C Nathan; Jennifer S Ford; Tara O Henderson; Melissa M Hudson; Karen M Emmons; Jacqueline N Casillas; E Anne Lown; Kirsten K Ness; Kevin C Oeffinger Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Toana Kawashima; Melissa M Hudson; Anna T Meadows; Debra L Friedman; Neyssa Marina; Wendy Hobbie; Nina S Kadan-Lottick; Cindy L Schwartz; Wendy Leisenring; Leslie L Robison Journal: N Engl J Med Date: 2006-10-12 Impact factor: 176.079
Authors: Emily S Tonorezos; Richard J Cohn; Adam W Glaser; Jeremy Lewin; Eileen Poon; Claire E Wakefield; Kevin C Oeffinger Journal: Lancet Date: 2022-04-16 Impact factor: 202.731
Authors: Lisa B Kenney; Lynda M Vrooman; Eileen Duffey Lind; Jill Brace-O'Neill; Jean E Mulder; Larissa Nekhlyudov; Christopher J Recklitis Journal: Pediatr Blood Cancer Date: 2021-02-08 Impact factor: 3.838
Authors: A V Mellblom; C E Kiserud; C S Rueegg; E Ruud; J H Loge; S D Fosså; Hanne C Lie Journal: Support Care Cancer Date: 2020-10-03 Impact factor: 3.603